Pinnacle Associates’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Pinnacle Associates’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-35,630	Closed	-$135K	–	713
2020 Q1	$135K	Sell	35,630 -6,350	-15%	-$27.4K	﹤0.01%	623
2019 Q4	$214K	Sell	41,980 -1,215,118	-97%	-$6.43M	﹤0.01%	667
2019 Q3	$6.36M	Sell	1,257,098 -41,625	-3%	-$208K	0.15%	166
2019 Q2	$8.01M	Sell	1,298,723 -119,668	-8%	-$577K	0.19%	148
2019 Q1	$6.58M	Sell	1,418,391 -26,475	-2%	-$120K	0.15%	173
2018 Q4	$6.07M	Sell	1,444,866 -85,791	-6%	-$437K	0.16%	167
2018 Q3	$9.6M	Sell	1,530,657 -258,416	-14%	-$1.99M	0.2%	137
2018 Q2	$14.4M	Sell	1,789,073 -312,595	-15%	-$2.39M	0.3%	94
2018 Q1	$15.7M	Sell	2,101,668 -111,450	-5%	-$741K	0.31%	91
2017 Q4	$13.2M	Sell	2,213,118 -171,715	-7%	-$1.04M	0.25%	101
2017 Q3	$17.6M	Sell	2,384,833 -70,085	-3%	-$445K	0.32%	85
2017 Q2	$16.7M	Sell	2,454,918 -98,520	-4%	-$727K	0.32%	87
2017 Q1	$24.1M	Sell	2,553,438 -111,502	-4%	-$1.11M	0.46%	63
2016 Q4	$23M	Sell	2,664,940 -149,600	-5%	-$1.11M	0.46%	64
2016 Q3	$17.8M	Sell	2,814,540 -30,380	-1%	-$184K	0.36%	84
2016 Q2	$12M	Buy	+2,844,920	New	+$13.7M	0.26%	109

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Pinnacle Associates's PGNX Position: Q2 2020 in Review

Pinnacle Associates sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 35,630 shares — an estimated $135K sold.

Pinnacle Associates first reported a position in PGNX in Q2 2016 and held it in 16 quarters. The position peaked at $24.1M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Pinnacle Associates reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Pinnacle Associates sold 35,630 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $135K.
Pinnacle Associates first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and held it in 16 quarters.
Pinnacle Associates's Progenics Pharmaceuticals Inc position peaked at $24.1M in Q1 2017.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Pinnacle Associates's 13F filing for Q2 2020, filed 14 Aug 2020.